Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010

Oct 28, 2010, 13:31 ET from Cumberland Pharmaceuticals Inc.

NASHVILLE, Tenn., Oct. 28 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will release third quarter 2010 financial results after the market closes on Thursday, November 11, 2010.  A conference call and live Internet webcast will be held on Thursday, November 11, 2010 at 5:00 p.m. Eastern Time to discuss the results.

To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 800-642-1687 (for U.S. callers) or 706-645-9291 (for international callers).  The Conference ID for the rebroadcast is 21780077.  The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.

Investor Contact:

Angela Novak

Corporate Relations

615-255-0068

anovak@cumberlandpharma.com

Media Contact:

Rebecca Kirkham

Lovell Communications

615-297-7766

rebecca@lovell.com

SOURCE Cumberland Pharmaceuticals Inc.



RELATED LINKS

http://www.cumberlandpharma.com